Astellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $13.54 and traded as high as $14.8610. Astellas Pharma shares last traded at $14.79, with a volume of 105,914 shares traded.

Analyst Ratings Changes

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Astellas Pharma Price Performance

The business’s 50-day moving average price is $13.54 and its 200 day moving average price is $14.65. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $26.76 billion, a P/E ratio of 11.26 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).